|
Apr 18
|
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
|
|
Apr 17
|
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
|
|
Mar 27
|
Immutep Limited (ASX:IMM): Is Breakeven Near?
|
|
Mar 24
|
11 Best ASX Stocks To Buy Now
|
|
Mar 5
|
Immutep Announces First Clinical Data from 90mg Dosing of Efti
|
|
Dec 21
|
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
|
|
Dec 7
|
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
|
|
Nov 27
|
Immutep (ASX:IMM) investors are sitting on a loss of 22% if they invested five years ago
|
|
Oct 23
|
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
|
|
Oct 18
|
It May Be Possible That Immutep Limited's (ASX:IMM) CEO Compensation Could Get Bumped Up
|
|
Sep 5
|
Immutep to Participate in September Investor Conferences
|
|
Aug 3
|
Qualcomm downgraded, Wingstop upgraded: Wall Street's top analyst calls
|